High Court Rules on Moderna-Pfizer/BioNTech COVID-19 Vaccine Patent Dispute, Setting Precedent for mRNA Technology Rights
核心洞察
The High Court delivered a mixed ruling in the patent battle between Moderna and Pfizer/BioNTech over COVID-19 (搜索) vaccine technology, finding one Moderna patent invalid while upholding another.
The court established that Moderna's October 2020 pledge not to enforce COVID-19 (搜索) patents provided legal consent to competitors but was effectively withdrawn in March 2022.
Pfizer/BioNTech will be liable for damages on UK sales of Comirnaty after March 7, 2022, with the case highlighting the critical importance of foundational mRNA (搜索) technology patents.
A landmark High Court ruling in the multimillion-pound patent dispute between COVID-19 (搜索) vaccine manufacturers has established critical precedents for mRNA (搜索) technology rights and pandemic-era patent pledges. The decision, delivered by Mr Justice Meade in July, addressed competing claims between Moderna and the Pfizer/BioNTech partnership over fundamental coronavirus vaccine patents.
Mixed Patent Validity Ruling
The court reached divergent conclusions on two key Moderna patents central to mRNA (搜索) vaccine technology. European Patent (UK) No. 3 718 565 (EP565), which covers betacoronavirus (搜索) mRNA vaccines encoding spike proteins formulated into lipid nanoparticles, was deemed invalid on grounds of obviousness and added matter, despite Pfizer/BioNTech's admission of infringement.
However, the court upheld the validity of European Patent (UK) No. 3 590 949 (EP949), which concerns the specific nucleotides used in mRNA (搜索) vaccines such as Comirnaty. Pfizer/BioNTech admitted infringing this patent, establishing their liability for damages on UK sales.
Landmark Interpretation of Pandemic Patent Pledge
The ruling represents the first global judicial interpretation of Moderna's October 8, 2020 public pledge not to enforce COVID-19 (搜索) patents against vaccine developers during the pandemic. The court found that this statement constituted legal "consent" under section 60 of the UK Patents Act 1977, providing Pfizer/BioNTech with a valid defense against infringement claims.
Critically, the court determined that Moderna's pledge remained effective from October 8, 2020, until March 7, 2022, when a subsequent public statement effectively withdrew the original commitment by limiting non-enforcement to low and middle-income countries only. The court rejected Pfizer/BioNTech's argument that the pledge continued until May 5, 2023, when the WHO declared the end of the COVID-19 (搜索) public health emergency.
Financial Implications and Appeal Process
The financial stakes are substantial, with combined legal costs reaching an estimated £19 million. Moderna's legal expenses total approximately £9.4 million, while Pfizer and BioNTech's costs amount to roughly £9.9 million. Andrew Waugh KC, representing Moderna, characterized the amounts at stake as "at the very highest end of the scale for a patent dispute."
Pfizer and BioNTech have been granted permission to appeal the EP949 decision to the Court of Appeal, while Moderna was denied permission to appeal the EP565 ruling, though the company may seek direct appeal to the higher court.
Global Patent Battle Continues
The UK proceedings form part of a broader international dispute, with parallel litigation ongoing in Ireland, Germany, the Netherlands, Belgium, and the United States. The global nature of the conflict reflects the critical importance of foundational mRNA (搜索) technology patents that extend beyond COVID-19 (搜索) applications.
As Ian Turner of Pinsent Masons noted, the ruling "brings into focus the importance of foundational mRNA (搜索) technology that is critical for a class of therapeutics with great promise more widely." This significance is underscored by Moderna's recent FDA approval for an mRNA vaccine against respiratory syncytial virus for older adults.
Implications for Future Patent Pledges
The decision establishes important precedents for corporate patent pledges during public health emergencies. Turner warned that "patent holders should take heed of the potential ramifications of statements seeking good PR. Only make comments about not enforcing patents against competitors if you wish to stick to your word, at least for the UK."
The court's interpretation that patent pledges can be withdrawn through subsequent public statements provides clarity for future pandemic preparedness strategies while highlighting the legal risks of informal patent commitments.
Subject to appeal outcomes, Pfizer/BioNTech will be liable for damages on Comirnaty sales in the UK after March 7, 2022, though they may continue selling the vaccine as Moderna has not sought injunctive relief. The final damage calculation will be determined in a separate trial.